Voltaren News and Research

RSS
Voltaren is a drug that is used to treat the symptoms of rheumatoid arthritis and is being studied in the prevention and treatment of some types of skin cancer. It blocks substances that cause inflammation and pain. It may also prevent the growth of new blood vessels that tumors need to grow. It is a type of cyclooxygenase inhibitor, a type of nonsteroidal anti-inflammatory drug (NSAID), and a type of antiangiogenesis agent. Also called diclofenac sodium.
Combined approach needed to address oral health inequalities and systemic health burden

Combined approach needed to address oral health inequalities and systemic health burden

BodyGuard wearable patch product shows superiority to common NSAID treatments in restoring joint function

BodyGuard wearable patch product shows superiority to common NSAID treatments in restoring joint function

New review points to most promising areas for liposomes' further development

New review points to most promising areas for liposomes' further development

Endo International’s revenues increase $800 million to 37% in fourth quarter 2014

Endo International’s revenues increase $800 million to 37% in fourth quarter 2014

Endo International revenues increase $719M to 1% in Q2 2014

Endo International revenues increase $719M to 1% in Q2 2014

Endo Health Solutions Reports net loss of $776M in fourth quarter 2013

Endo Health Solutions Reports net loss of $776M in fourth quarter 2013

Study confirms that COX-2 inhibitors predispose people to cardiovascular disease

Study confirms that COX-2 inhibitors predispose people to cardiovascular disease

Endo fourth quarter total revenues increase 57% to $803.4 million

Endo fourth quarter total revenues increase 57% to $803.4 million

Endo enters global development agreement with BDSI for BEMA Buprenorphine

Endo enters global development agreement with BDSI for BEMA Buprenorphine

Endo, BDSI partner to develop and commercialize BEMA Buprenorphine for chronic pain

Endo, BDSI partner to develop and commercialize BEMA Buprenorphine for chronic pain

BioLineRx, Tel Aviv University sign license agreement to develop and commercialize BL-7050

BioLineRx, Tel Aviv University sign license agreement to develop and commercialize BL-7050

Cardium to purchase Transdel's business assets

Cardium to purchase Transdel's business assets

Endo fourth quarter total revenues increase 31% to $511 million

Endo fourth quarter total revenues increase 31% to $511 million

Painkillers and heart attack risk

Painkillers and heart attack risk

Endo third quarter total revenues increase 23% to $444.1 million

Endo third quarter total revenues increase 23% to $444.1 million

Stroke risk with common pain killers dismissed by manufacturer

Stroke risk with common pain killers dismissed by manufacturer

Endo Pharmaceuticals total revenues for second-quarter 2010 increase 6% to $396.5 million

Endo Pharmaceuticals total revenues for second-quarter 2010 increase 6% to $396.5 million

Endo acquires HealthTronics

Endo acquires HealthTronics

Endo subsidiary successfully completes tender offer for HealthTronics' outstanding common stock

Endo subsidiary successfully completes tender offer for HealthTronics' outstanding common stock

Endo responds to FDA Complete Response letter for FORTESTA NDA

Endo responds to FDA Complete Response letter for FORTESTA NDA